Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
New Hampshire: below-average open trial sites
155 of 471 in-state trials are recruiting (33%); below the 37% national average by 4 percentage points.
According to ClinicalTrials.gov-derived indexes, New Hampshire sits in the lower half of US states by in-state trial count (#43 of 52 states by registered in-state trial count).
New Hampshire: 471 US clinical trials with in-state sites, 155 recruiting.
New Hampshire has 471 registered US clinical trials with a study site in-state, 155 of them currently recruiting (below the 37% national average by 4 percentage points). 83 of these trials are in Phase 3 (late-stage) and 101 in Phase 2. The most frequently studied condition in New Hampshire is Breast Cancer, with 23 linked trials.
Thin-volume New Hampshire archive
New Hampshire's in-state trials target 689 patients on average (p10 by trial size among 52 states with enrollment data), smaller studies than most states. Treat this page as a compact local index (thin-volume · mid-open), then jump to recruiting trials or methodology rather than expecting hub-scale coverage.
Below-average open enrollment
New Hampshire still shows 155 recruiting of 471 in-state trials (33% open), but below the 37% national average by 4 percentage points, so archived statuses weigh heavier than the national baseline.
- 33%
- open (below national share)
- 155
- still recruiting despite cool share
- 101
- Phase 2 rows in this footprint
- 23
- top: Breast Cancer
Recruiting share is below the 37% national average by 4 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
New Hampshire vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
471 Top 83% more indexed trials than 17% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for New Hampshire on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
New Hampshire open-enrollment share sits below the national baseline.
155 of 471 in-state trials (32.9%) are recruiting, against 37% nationally (-4.1 percentage points). Counts include every study with at least one recorded site in the state.
-
Lebanon dominates New Hampshire's trial geography.
Lebanon lists 365 of 471 in-state trials (77.5%) across 91 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Breast Cancer is the most-studied condition in New Hampshire.
23 of 471 in-state trials (4.9%) list Breast Cancer. That is a local concentration figure, not a national disease ranking.
-
One sponsor accounts for a large share of New Hampshire trials.
Dartmouth-Hitchcock Medical Center appears on 117 of 471 in-state trials (24.8%). Sponsor identity is as filed on ClinicalTrials.gov.
-
216 New Hampshire trials carry a completed status.
216 of 471 (45.9%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Completed | 216 |
| Recruiting | 155 |
| Active | 100 |
By Phase
| Phase | Trial count |
|---|---|
| NA | 148 |
| Phase 2 | 101 |
| Phase 3 | 83 |
| Phase 1 | 52 |
| Phase 4 | 8 |
| Early Phase 1 | 4 |
Top Conditions
Top Sponsors
Where trials run in New Hampshire
Lebanon carries 365 of New Hampshire's 471 indexed trials (77%) across 91 named sites, ahead of Manchester at 33. 7 cities clear five listed trials, together naming 168 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Lebanon | 365 | 91 |
| Manchester | 33 | 20 |
| Portsmouth | 20 | 18 |
| Hanover | 15 | 10 |
| Londonderry | 14 | 8 |
| Nashua | 13 | 12 |
| Concord | 10 | 9 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Trial size small
New Hampshire's in-state trials target 689 patients on average (p10 by trial size among 52 states with enrollment data), smaller studies than most states.
New Hampshire: in-state trial volume sits in the thin tercile
Geography is concentrated: Lebanon alone accounts for 77% of New Hampshire's indexed trials (365 of 471), with Manchester a distant second at 33.
Phase mix: 83 Phase 3 vs 101 Phase 2 (balanced across stages).
Top condition: Breast Cancer (23 trials); top sponsor Dartmouth-Hitchcock Medical Center (117).
thin-volume · mid-open figures (471 trials · 33% open) describe registry geography under the trial size small read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near New Hampshire on in-state trial volume
Cross-state peers under the trial size small read (thin-volume · mid-open), not the same-state browse list.
Similar thin-volume peers (± open share)
- Alaska · 485 trials · 25% recruiting
- Mississippi · 500 trials · 27% recruiting
- Hawaii · 437 trials · 26% recruiting
- New Mexico · 579 trials · 29% recruiting
- Maine · 315 trials · 23% recruiting
Similar mid-open peers (± trial volume)
- Iowa · 33% recruiting · 1,544 trials
- California · 33% recruiting · 16,646 trials
- North Carolina · 33% recruiting · 5,625 trials
- Florida · 33% recruiting · 10,986 trials
- Washington · 33% recruiting · 2,795 trials